Accelerating Therapeutic DiscoveryTM

News From The Alpha-1 Project

Entries for January 2019


Scientific founders who originated the miRNA mediated “silence and replace” approach take on Alpha-1 and ALS

US patent awarded for its proprietary THRIVE™ platform

Appoints new Chief Technology Officer with rAAV gene therapy cGMP manufacturing and virology expertise


Apic Bio, Inc. an innovative gene therapy company developing best-in-class treatment options for patients with rare genetic diseases, today announced the completion of a $40 million Series A financing led by Morningside Venture. Existing investors, The Alpha-1 Project (TAP) and A1ATD Investors, LLC also participated along with new investor, the ALS Investment Fund.

[Read More...]